Following a standard, uncomplicated primary total hip arthroplasty in a patient with absolutely no prior history of venous thromboembolism (VTE) and no known hypercoagulable genetic state, what is the American College of Chest Physicians (ACCP) strongly endorsed pharmaceutical agent for routine, standard-risk VTE prophylaxis?

Explanation:
The correct option is d. The prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) following arthroplasty requires balancing the risk of clotting against the catastrophic risk of a massive postoperative bleeding hematoma or periprosthetic infection. For standard-risk patients, aggressive anticoagulation (like warfarin or continuous heparin) causes unacceptable bleeding rates without providing superior mortality benefits. The ACCP, AAOS, and massive consensus guidelines strongly endorse Aspirin (due to its safety, low cost, and proven efficacy) or Low-Molecular-Weight Heparins (LMWH, like Enoxaparin) or direct oral anticoagulants (DOACs) as the standard of care for a typical duration of 2 to 6 weeks. Reference: Falck-Ytter Y et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.